New Study Shows Blood Glucose Measurements Can Accurately Estimate Hemoglobin A1c in Diabetes

NEW ROCHELLE, N.Y. - April 22, 2014 - PRLog -- New Rochelle, NY—Hemoglobin A1c is the standard measurement for assessing glycemic control over time in people with diabetes. Blood levels of A1c are typically measured every few months in a laboratory, but now researchers have developed a data-based model that accurately estimates A1c using self-monitored blood glucose (SMBG) readings, as described in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the DTT website at http://www.liebertpub.com/dtt.

In “Accuracy and Robustness of Dynamical Tracking of Average Glycemia (A1c) to Provide Real-Time Estimation of Hemoglobin A1c Using Routine Self-Monitored Blood Glucose Data” (http://online.liebertpub.com/doi/full/10.1089/dia.2013.0224), authors Boris Kovatchev, PhD, Frank Flacke, PhD, Jochen Sieber, MD, and Marc Breton, PhD present the computer algorithm they developed based on a training data set drawn from 379 subjects and then evaluated for accuracy on an independent test data set. The authors propose that estimation of real-time A1c could increase individuals' motivation to improve diabetes control.

“Patients are used to an A1c result from their doctor visits, and this study highlights simple estimated A1c values from SMBG data,” says Satish Garg, MD, Editor-in-Chief of Diabetes Technology & Therapeutics and Professor of Medicine and Pediatrics at the University of Colorado Denver. “This may become an important tool for improved patient self-management.”

About the Journal
Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver, the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of content and a sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) website at http://www.liebertpub.com/dtt. DTT is the official journal of the Advanced Technologies & Treatments for Diabetes (ATTD) Conference.

About ATTD
The International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) presents top-caliber scientific programs that have provided participants with cutting-edge research and analysis into the latest developments in diabetes-related technology. A unique and innovative conference, ATTD brings the world’s leading researchers and clinicians together for a lively exchange of ideas and information related to the technology, treatment, and prevention of diabetes and related illnesses.

About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Thyroid, Metabolic Syndrome and Related Disorders, Journal of Aerosol Medicine and Pulmonary Drug Delivery, Childhood Obesity, and Population Health Management. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website at http://www.liebertpub.com.

Mary Ann Liebert, Inc.    140 Huguenot St., New Rochelle, NY 10801-5215    www.liebertpub.com
Phone: (914) 740-2100    (800) M-LIEBERT    Fax:  (914) 740-2101